The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Evaluating RO7443904 in combination with glofitamab in patients with R/R NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, shares some insights into a study evaluating the use of RO7443904, a bispecific antibody-like fusion protein, in combination with glofitamab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genmab: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; AbbVie: Consultancy; Incyte: Research Funding; Janssen: Consultancy, Research Funding; AbbVie, Celgene, Genmab, Janssen, Roche, Takeda: Membership on an entity’s Board of Directors or advisory committees; Genentech: Research Funding; Novartis: Research Funding; Celgene, Genentech, Genmab, Incyte, Janssen, Novartis, Roche, Takeda: Research Funding; Roche: Consultancy, Research Funding; Takeda: Consultancy, Research Funding.
